WO2008024408A3 - Formulations pharmaceutiques de cannabinoïdes destinées à être appliquées sur la peau et leur procédé d'utilisation - Google Patents

Formulations pharmaceutiques de cannabinoïdes destinées à être appliquées sur la peau et leur procédé d'utilisation Download PDF

Info

Publication number
WO2008024408A3
WO2008024408A3 PCT/US2007/018585 US2007018585W WO2008024408A3 WO 2008024408 A3 WO2008024408 A3 WO 2008024408A3 US 2007018585 W US2007018585 W US 2007018585W WO 2008024408 A3 WO2008024408 A3 WO 2008024408A3
Authority
WO
WIPO (PCT)
Prior art keywords
skin
application
cannabinoids
pharmaceutical formulations
cannabinoid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/018585
Other languages
English (en)
Other versions
WO2008024408A2 (fr
Inventor
Najib Babul
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Relmada Therapeutics Inc
Original Assignee
Theraquest Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theraquest Biosciences Inc filed Critical Theraquest Biosciences Inc
Publication of WO2008024408A2 publication Critical patent/WO2008024408A2/fr
Publication of WO2008024408A3 publication Critical patent/WO2008024408A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7092—Transdermal patches having multiple drug layers or reservoirs, e.g. for obtaining a specific release pattern, or for combining different drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des compositions pharmaceutiques d'agonistes des cannabinoïdes destinées à être appliquées sur la peau et leur utilisation pour empêcher ou minimiser le risque qu'un abus d'agonistes des cannabinoïdes et/ou que la toxicité des agonistes des cannabinoïdes soit masqué intentionnellement ou non. La présente invention concerne également un procédé consistant à empêcher ou minimiser le risque qu'un abus d'agonistes des cannabinoïdes et/ou que la toxicité des agonistes des cannabinoïdes soit masqué intentionnellement ou non.
PCT/US2007/018585 2006-08-22 2007-08-22 Formulations pharmaceutiques de cannabinoïdes destinées à être appliquées sur la peau et leur procédé d'utilisation Ceased WO2008024408A2 (fr)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US83911506P 2006-08-22 2006-08-22
US83911706P 2006-08-22 2006-08-22
US60/839,117 2006-08-22
US60/839,115 2006-08-22
US84096906P 2006-08-30 2006-08-30
US84097106P 2006-08-30 2006-08-30
US60/840,969 2006-08-30
US60/840,971 2006-08-30

Publications (2)

Publication Number Publication Date
WO2008024408A2 WO2008024408A2 (fr) 2008-02-28
WO2008024408A3 true WO2008024408A3 (fr) 2008-10-23

Family

ID=39107387

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/018585 Ceased WO2008024408A2 (fr) 2006-08-22 2007-08-22 Formulations pharmaceutiques de cannabinoïdes destinées à être appliquées sur la peau et leur procédé d'utilisation

Country Status (1)

Country Link
WO (1) WO2008024408A2 (fr)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
WO2010056309A2 (fr) * 2008-11-14 2010-05-20 The Scripps Research Institute Procédé et composition se rapportant au ciblage de la mono-acylglycérol lipase
DE102009036485B4 (de) * 2009-08-07 2012-10-04 Lts Lohmann Therapie-Systeme Ag Mittel zur zerstörenden Entsorgung von medizinischen Wirkstoffen in transdermalen therapeutischen Systemen
EP3834869B1 (fr) 2010-12-22 2024-06-05 Syqe Medical Ltd. Système d'administration de médicament
WO2013006643A1 (fr) 2011-07-06 2013-01-10 The Parkinson's Institute Compositions et méthodes de traitement de symptômes chez des patients atteints de la maladie de parkinson
EP2968259B1 (fr) 2013-03-14 2022-09-14 SC Laboratories Inc. Concentrés bioactifs et leurs utilisations
CN115444659A (zh) * 2014-01-22 2022-12-09 4P治疗公司 滥用和误用制止透皮系统
US20160022627A2 (en) * 2014-04-18 2016-01-28 Mary's Medicinals LLC Transdermal cannabinoid patch
US11298477B2 (en) 2014-06-30 2022-04-12 Syqe Medical Ltd. Methods, devices and systems for pulmonary delivery of active agents
IL273507B2 (en) 2014-06-30 2024-06-01 Syqe Medical Ltd Methods, devices and systems for administering active substances through the lungs
RU2721064C2 (ru) 2014-06-30 2020-05-15 Сике Медикал Лтд. Ингалятор с регулированием потока
AU2015283589B2 (en) 2014-06-30 2019-09-12 Syqe Medical Ltd. Method and device for vaporization and inhalation of isolated substances
RU2723335C2 (ru) 2014-06-30 2020-06-09 Сике Медикал Лтд. Дозовый картридж для ингалятора
CN113616883B (zh) 2014-06-30 2023-06-06 Syqe医药有限公司 向受试者肺部递送植物材料中的至少一药理活性剂的系统
US9375417B2 (en) 2014-12-04 2016-06-28 Mary's Medicinals LLC Transdermal cannabinoid formulations
US10028904B2 (en) 2014-12-04 2018-07-24 Wisconsin Alumni Research Foundation Transdermal cannabinoid formulations
AU2016211330A1 (en) 2015-01-28 2017-08-03 Chrono Therapeutics Inc. Drug delivery methods and systems
WO2016133824A1 (fr) * 2015-02-16 2016-08-25 Axim Biotechnologies, Inc. Compositions cosmétiques et topiques comprenant du cannabigérol
AU2016225026A1 (en) * 2015-02-27 2017-09-07 Canopy Growth Corporation Compositions comprising combinations of purified cannabinoids, with at least one flavonoid, terpene, or mineral
CN107427472B (zh) * 2015-03-02 2021-04-30 久光制药株式会社 贴附剂
US10679516B2 (en) 2015-03-12 2020-06-09 Morningside Venture Investments Limited Craving input and support system
US9962340B2 (en) * 2015-06-09 2018-05-08 Life Tech Global, Llc Device and method for the transdermal delivery of cannabidiol
CA2995418A1 (fr) * 2015-08-11 2017-02-16 KannaInnovations LLC Compositions topiques comprenant des hydroxyacides et des cannabinoides pour les soins de la peau
US10272125B2 (en) * 2015-09-14 2019-04-30 Life Tech Global, Llc Transdermal delivery of cannabidiol with other active moieties including cannabinoids
US10966936B2 (en) 2015-12-30 2021-04-06 Corium, Inc. Systems comprising a composite backing and methods for long term transdermal administration
CA3009599A1 (fr) 2016-01-06 2017-07-13 Syqe Medical Ltd. Traitement therapeutique a faible dose
AU2017229125B2 (en) 2016-03-08 2021-07-29 Living Proof, Inc. Long lasting cosmetic compositions
US10973786B2 (en) 2016-03-11 2021-04-13 Axcess Global Sciences, Llc R-beta-hydroxybutyrate, S-beta-hydroxybutyrate, and RS-beta-hydroxybutyrate mixed salt compositions
US10245243B1 (en) 2017-12-19 2019-04-02 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use
US10736861B2 (en) 2016-03-11 2020-08-11 Axcess Global Sciences, Llc Mixed salt compositions for producing elevated and sustained ketosis
US10596130B2 (en) 2017-12-19 2020-03-24 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use
US10973792B2 (en) 2019-02-13 2021-04-13 Axcess Global Sciences, Llc Racemic beta-hydroxybutyrate mixed salt-acid compositions and methods of use
US11185518B2 (en) 2017-12-19 2021-11-30 Axcess Global Sciences, Llc S-beta-hydroxybutyrate compounds and compositions enriched with S-enantiomer
US10596131B2 (en) 2017-11-22 2020-03-24 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US11103470B2 (en) 2017-11-22 2021-08-31 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US11241403B2 (en) 2016-03-11 2022-02-08 Axcess Global Sciences, Llc Beta-hydroxybutyrate mixed salt compositions and methods of use
US10596129B2 (en) 2017-11-22 2020-03-24 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US10245242B1 (en) 2017-11-22 2019-04-02 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US12533346B2 (en) 2016-04-19 2026-01-27 Axcess Global Sciences, Llc Administration of berberine metabolites
US12329734B2 (en) 2017-12-19 2025-06-17 Axcess Global Sciences, Llc Use of S-beta-hydroxybutyrate compounds for induction and maintenance of flow
US12521378B2 (en) 2016-04-19 2026-01-13 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate salt blend and related compounds in humans
US10925843B2 (en) 2018-04-18 2021-02-23 Axcess Global Sciences, Llc Compositions and methods for keto stacking with beta-hydroxybutyrate and acetoacetate
US12496283B2 (en) 2016-04-19 2025-12-16 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate and related compounds in humans
US11202769B2 (en) 2017-11-22 2021-12-21 Axcess Global Sciences, Llc Ketone body esters of s-beta-hydroxybutyrate and/or s-1,3-butanediol for modifying metabolic function
US11806324B2 (en) 2018-04-18 2023-11-07 Axcess Global Sciences, Llc Beta-hydroxybutyric acid compositions and methods for oral delivery of ketone bodies
US12109182B2 (en) 2016-04-19 2024-10-08 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate and related compounds in humans
US12599579B2 (en) 2016-04-19 2026-04-14 Axcess Global Sciences, Llc Compositions and compounds containing ketone bodies and/or ketone body precursors and one or more amino acids
US20230346721A1 (en) 2018-04-18 2023-11-02 Axcess Global Sciences, Llc Beta-hydroxybutyric acid compositions and methods for delivery of ketone bodies
US11944598B2 (en) 2017-12-19 2024-04-02 Axcess Global Sciences, Llc Compositions containing s-beta-hydroxybutyrate or non-racemic mixtures enriched with the s-enatiomer
BR112018071518A2 (pt) 2016-04-22 2019-02-19 Receptor Life Sciences, Inc. compostos medicinais à base de planta de ação rápida e suplementos nutricionais
WO2018000094A1 (fr) 2016-06-29 2018-01-04 CannScience Innovations Inc. Résines de cannabis décarboxylées, leurs utilisations et leurs procédés de fabrication
US12485129B2 (en) 2016-08-29 2025-12-02 Canopy Growth Corporation Water soluble compositions comprising purified cannabinoids
MX380850B (es) 2016-08-29 2025-03-12 Canopy Growth Corp Composiciones solubles en agua que comprenden cannabinoides purificadas
EA201892396A1 (ru) 2016-12-02 2019-04-30 Ресептор Лайф Сайенсиз, Инк. Быстродействующие растительные лекарственные соединения и биологически активные добавки
CA3049529A1 (fr) 2017-01-06 2018-07-12 Chrono Therapeutics Inc. Dispositifs et methodes d'administration transdermique de medicament
US20220323401A1 (en) * 2017-02-15 2022-10-13 Botanix Pharmaceuticals Ltd. Formulations of cannabinoids for the treatment of acne
JP2020508991A (ja) * 2017-02-15 2020-03-26 ボタニクス ファーマシューティカルズ リミテッド 乾癬の処置のためのカンナビノイドの製剤
JP7012089B2 (ja) * 2017-02-15 2022-01-27 ボタニクス ファーマシューティカルズ リミテッド 皮膚炎および炎症性皮膚疾患の処置のためのカンナビノイドの製剤
WO2018148787A1 (fr) * 2017-02-15 2018-08-23 Botanix Pharmaceuticals Ltd Formulations de cannabinoïdes pour le traitement du psoriasis
WO2018148786A1 (fr) * 2017-02-15 2018-08-23 Botanix Pharmaceuticals Ltd Formulations de cannabinoïdes pour le traitement de l'acné
WO2018148785A1 (fr) * 2017-02-15 2018-08-23 Botanix Pharmaceuticals Ltd Formulations de cannabinoïdes pour le traitement de la dermatite et de maladies cutanées inflammatoires
US20210128518A1 (en) * 2017-03-06 2021-05-06 Jack D. Korbutov Cannabinoid-containing dermatological compositions and methods using same
JP6801554B2 (ja) * 2017-03-29 2020-12-16 東洋インキＳｃホールディングス株式会社 皮膚貼付用粘着剤、皮膚用貼付剤、および剥離用シート状部材付き皮膚用貼付剤の製造方法
CN106943235A (zh) * 2017-03-31 2017-07-14 南阳医学高等专科学校 一种剖腹产术后护腹带
AU2018333932B2 (en) 2017-09-13 2024-05-02 Living Proof, Inc. Long lasting cosmetic compositions
EP3681921A2 (fr) 2017-09-13 2020-07-22 Living Proof, Inc. Compositions de protection de couleur
SG11202003505RA (en) * 2017-10-17 2020-07-29 Remy Biosciences Inc Improved delivery systems for moieties including cbd enhanced combinations, formulations and chimeras
CN111356501A (zh) 2017-11-20 2020-06-30 生活实验公司 实现持久化妆品性能的属性
US12090129B2 (en) 2017-11-22 2024-09-17 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
CN107997882A (zh) * 2017-12-07 2018-05-08 云南汉木森生物科技有限责任公司 一种具有抗菌消炎、止痛功效的卫生巾及其制作方法
CA3085342A1 (fr) * 2017-12-13 2019-06-20 Corium, Inc. Methode de creation de depot pendant l'administration transdermique de medicament
WO2019144190A1 (fr) 2018-01-24 2019-08-01 Botanix Pharmaceuticals Ltd Régime de dosage de cannabinoïde pour dermatite et affections cutanées inflammatoires
US10512615B1 (en) 2018-08-27 2019-12-24 Axcess Global Sciences, Llc Compositions and methods for delivering cannabidiol and ketone bodies
US11241401B2 (en) 2020-02-06 2022-02-08 Axcess Global Sciences, Llc Enantiomerically pure r-beta-hydroxybutyrate mixed salt-acid compositions
US11129802B2 (en) 2018-08-27 2021-09-28 Axcess Global Sciences, Llc Compositions and methods for delivering cannabidiol and ketone bodies
US11419836B2 (en) 2019-02-13 2022-08-23 Axcess Global Sciences, Llc Racemic and near racemic beta-hydroxybutyrate mixed salt-acid compositions
US10980772B2 (en) * 2018-08-27 2021-04-20 Axcess Global Sciences, Llc Compositions and methods for delivering tetrahydrocannabinol and ketone bodies
BR112020021902B1 (pt) 2018-04-27 2024-02-20 Living Proof, Inc Composições cosméticas de poliuretano-ureia para tratamento capilar, método de preservação da ondulação no cabelo humano e os usos de poliuretano-ureia
US11596779B2 (en) 2018-05-29 2023-03-07 Morningside Venture Investments Limited Drug delivery methods and systems
US12397141B2 (en) 2018-11-16 2025-08-26 Morningside Venture Investments Limited Thermally regulated transdermal drug delivery system
EP3883595A4 (fr) 2018-11-19 2022-12-14 Receptor Holdings, Inc. N-acides aminés gras n-acylés pour réduire la variabilité d'absorption dans des compositions à base de cannabinoïdes
WO2020183350A1 (fr) * 2019-03-12 2020-09-17 Radient Technologies Innovations Inc. Kit de timbre transdermique avec des unités posologiques transdermiques
US12472200B2 (en) 2019-05-15 2025-11-18 Axcess Global Sciences, Llc Autobiotic compositions and method for promoting healthy gut microbiome
US12167993B2 (en) 2019-06-21 2024-12-17 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
US11950616B2 (en) 2019-06-21 2024-04-09 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
US11033553B2 (en) 2019-06-21 2021-06-15 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
US11969430B1 (en) 2023-03-10 2024-04-30 Axcess Global Sciences, Llc Compositions containing paraxanthine and beta-hydroxybutyrate or precursor for increasing neurological and physiological performance
AU2020358869A1 (en) 2019-10-03 2022-04-14 Pike Therapeutics Usa, Inc. Transdermal delivery of dronabinol
US12409131B2 (en) 2019-10-03 2025-09-09 Pike Therapeutics Usa, Inc. Transdermal delivery of dronabinol
US12016829B2 (en) 2019-10-11 2024-06-25 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
EP4041209A4 (fr) 2019-10-11 2024-01-24 Pike Therapeutics, Inc. Compositions transdermiques comprenant du cannabidiol (cbd) destinées à être utilisées dans le traitement de troubles épileptiques
CA3155181A1 (fr) 2019-10-14 2021-04-22 Pike Therapeutics, Inc., 1219014 B.C. Ltd. Administration transdermique de cannabidiol
US12121617B2 (en) 2019-10-14 2024-10-22 Pike Therapeutics Inc. Transdermal delivery of cannabidiol
US12268699B2 (en) 2019-10-14 2025-04-08 Pike Therapeutics Inc. Transdermal delivery of tetrahydrocannabinol
US11355822B2 (en) * 2020-01-23 2022-06-07 Duracell U.S. Operations, Inc. Battery peel off assembly for exposing a safety feature comprising an aversive agent
WO2022046961A1 (fr) * 2020-08-26 2022-03-03 Babak Ghalili Systèmes et procédés d'administration transdermique de cannabinoïde et de menthol
US12186297B2 (en) 2020-08-26 2025-01-07 Axcess Global Sciences, Llc Compositions and methods for increasing lean-to-fat mass ratio
US11141404B1 (en) * 2020-11-18 2021-10-12 Anebulo Pharmaceuticals, Inc. Formulations and methods for treating acute cannabinoid overdose
CN113384558A (zh) * 2021-02-01 2021-09-14 深圳普洛美康材料有限公司 一种递送大麻活性物质的透皮贴剂
AU2022362107A1 (en) 2021-10-11 2024-05-02 Anebulo Pharmaceuticals, Inc. Crystalline forms of a cannabinoid receptor type 1 (cb1) modulator and methods of use and preparation thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030003113A1 (en) * 2001-06-29 2003-01-02 Lewandowski Leon J. Individualized addiction cessation therapy
US20030125659A1 (en) * 2000-05-25 2003-07-03 Wolfgang Fleischer Dosage of transdermal delivery systems

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030125659A1 (en) * 2000-05-25 2003-07-03 Wolfgang Fleischer Dosage of transdermal delivery systems
US20030003113A1 (en) * 2001-06-29 2003-01-02 Lewandowski Leon J. Individualized addiction cessation therapy

Also Published As

Publication number Publication date
WO2008024408A2 (fr) 2008-02-28

Similar Documents

Publication Publication Date Title
WO2008024408A3 (fr) Formulations pharmaceutiques de cannabinoïdes destinées à être appliquées sur la peau et leur procédé d'utilisation
WO2008021394A3 (fr) Formulations pharmaceutiques d'agonistes cannabinoïdes et procédé d'utilisation
WO2008027442A3 (fr) Formulations pharmaceutiques orales anti-abus à base d'opioïdes et procédé d'utilisation
WO2008024490A3 (fr) Formulations pharmaceutiques à usage oral de cannabinoïdes dissuadant les abus et leur procédé d'utilisation
WO2008033351A3 (fr) Formulations multimode de libération prolongée et résistantes à l'abus
WO2007087452A3 (fr) Formulations à libération prolongée empêchant l'usage abusif et méthodes d'utilisation de celles-ci
WO2008076754A3 (fr) Composés et compositions utilisés comme inhibiteurs de l'activité du récepteur cannabinoïde 1
WO2006047516A3 (fr) Composes et compositions servant d'inhibiteurs d'activite de recepteur cannabinoide de type 1
WO2008028965A3 (fr) Inhibiteurs de la protéine phosphatase 1, de gadd34 et du complexe protéine phosphatase 1/gadd34, leur préparation et leurs applications
WO2006096439A3 (fr) Compositions pharmaceutiques destinees au traitement et/ou a la prevention de la schizophrenie et de maladies associees
WO2007095043A3 (fr) Formulations pharmaceutiques
MX2008012400A (es) Azolopirimidinas como inhibidores de actividad de cannabinoide 1.
WO2008010921A3 (fr) Modulateurs de propriétés pharmacocinétiques d'agents thérapeutiques
CL2008000507A1 (es) Preparacion regioespecifica de 42-ester de rapamicina con acido 3-hidroxi-2-(hidroxi metil)-2- metil propionico, protegido con isopropilidencetal; y composicion farmaceutica que comprende a dicho compuesto.
MY146969A (en) Dpp iv inhibitor formulations
WO2008030744A3 (fr) Inhibiteurs de c-met et leurs utilisations
WO2008112164A3 (fr) Modulateurs de l'aldéhyde déshydrogénase-2 mitochondrial, et leurs procédés d'utilisation
WO2008001200A3 (fr) Composition transdermique à stabilité de couleur améliorée
WO2008105383A1 (fr) Dérivé de pyrazole et son utilisation pour des objectifs médicaux
WO2007109523A3 (fr) Procédés de stabilisation de compositions instables de manière oxydative
WO2004009091A8 (fr) Agonistes des recepteurs x du foie
WO2007135562A3 (fr) Nouveaux dérivés d'hydroxyphényle et leurs applications biologiques
WO2008075201A3 (fr) Compositions d'épigallocatéchine-3-gallate destinées au traitement du cancer et à la chimioprotection
AU2007310767A1 (en) New fluorene derivatives, compositions containing the same and use thereof as inhibitors of the protein chaperone HSP 90
WO2005046689A3 (fr) Utilisation d’un derive du pyrazole pour la prevention et le traitement des dyslipidemies et des maladies associees aux dyslipidemies et/ou a l’obesite

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07837213

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07837213

Country of ref document: EP

Kind code of ref document: A2